Price$2.69-0.06 (-2.36%)
03:15 PM04:00 PM
News · 26 weeks74-87%
2026-04-052026-09-27
Mix4690d
- Insider23(50%)
- SEC Filings11(24%)
- Other7(15%)
- Leadership3(7%)
- Earnings2(4%)
Latest news
25 items- SECLongeveron Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Longeveron Inc. (0001721484) (Filer)
- PRLongeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)Company Announces Exploration of All Options to Maximize Shareholder Value The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHSLaromestrocel has maintained what Longeveron believes is a favorable safety and tolerability profile consistent with prior clinical trials, now with 644 patients treated across Longeveron's multiple clinical programs, and has shown potential efficacy in clinical studies across multiple indication
- SECLongeveron Inc. filed SEC Form 8-K: Other Events8-K - Longeveron Inc. (0001721484) (Filer)
- PRLongeveron to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceMIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026 in New York City. Details for the Company’s presentation: Date:Monday, September 14, 2026 Time:1:00 – 1:30 p.m. ET The webcast for this conference presentation may be accessed at the "Events and Presentations" section of the Company’s website. About Longeveron Inc.Longeveron is a clinical stage biotechnology company developing
- INSIDERChief Financial Officer Jhaveri Nirav S. was granted 300,000 shares (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERNew insider Jhaveri Nirav S. claimed no ownership of stock in the company (SEC Form 3)3 - Longeveron Inc. (0001721484) (Issuer)
- SECLongeveron Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Longeveron Inc. (0001721484) (Filer)
- PRLongeveron Announces 1-for-10 Reverse Stock SplitMIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the "Common Stock") (the "2026 Reverse Split"). The 2026 Reverse Split was previously approved by the Company’s stockholders at the Company’s annual meeting held on July 1, 2026 and the Company’s Board of Directors on July 31, 2026. The 2026 Reverse Split is expected to become
- INSIDERChief Medical Officer Agafonova Nataliya was granted 286,000 shares, increasing direct ownership by 66% to 716,914 units (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERCTO & SVP of CMC Blass Devin was granted 286,000 shares, increasing direct ownership by 67% to 711,735 units (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERChief Scientific Officer Hare Joshua was granted 286,000 shares, increasing direct ownership by 22% to 1,607,796 units (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERDirector Ascheim Deborah was granted 36,000 shares (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERDirector Cann Leah Rush was granted 36,000 shares (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERDirector Soffer Rock was granted 36,000 shares, increasing direct ownership by 16% to 262,034 units (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERDirector Desai Arjun Jj was granted 36,000 shares (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERDirector Paletta George A. Jr. was granted 36,000 shares, increasing direct ownership by 106% to 70,000 units (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERDirector Ungaro Ursula was granted 36,000 shares, increasing direct ownership by 88% to 77,000 units (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERGeneral Counsel, Secretary Lehr Paul T was granted 286,000 shares, increasing direct ownership by 50% to 861,423 units (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERDirector Hajjar Roger Joseph was granted 36,000 shares, increasing direct ownership by 109% to 69,000 units (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- SECLongeveron Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Longeveron Inc. (0001721484) (Filer)
- PRLongeveron Appoints Nirav Jhaveri as Chief Financial OfficerMr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer ("CFO"), principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped into the role following the retirement of the
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Longeveron Inc.SCHEDULE 13G/A - Longeveron Inc. (0001721484) (Subject)
- SECLongeveron Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Longeveron Inc. (0001721484) (Filer)
- PRLongeveron Announces 2026 Second Quarter Financial Results and Provides Business UpdateOn track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indicationLongeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailtyThree new independent Directors join Longeveron’s Board of DirectorsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage
- SECSEC Form 10-Q filed by Longeveron Inc.10-Q - Longeveron Inc. (0001721484) (Filer)
LGVN FAQ
7 questionsWhat does Longeveron Inc. do?
Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was...Where does LGVN stock trade?
Longeveron Inc. (LGVN) is listed on NASDAQ.What sector and industry is LGVN in?
Longeveron Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Longeveron Inc. go public?
Longeveron Inc. (LGVN) completed its IPO in 2021.What are analysts saying about LGVN?
Longeveron Inc. has had 2 recent analyst actions on file. The most recent action was from ROTH MKM: Buy with a $1000.00 price target on 2024-12-06. Recent price targets range from $1000.00 to $2000.00.What companies are similar to LGVN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare LGVN side-by-side with any of them on Quantisnow.How can I track LGVN on Quantisnow?
Quantisnow aggregates Longeveron Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LGVN to receive live email and push alerts on every new disclosure.